A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma
Clinical trial NCT02519452 · COMPLETED
Trial details
- NCT number
- NCT02519452
- Sponsor
- Janssen Research & Development, LLC
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2015-10-22
- Primary completion
- 2017-12-13
- Enrollment
- 120
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.